BillionaireClubCollc
  • News
  • Notifications
  • Shop
  • Cart
  • Media
  • Advertise with Us
  • Profile
  • Groups
  • Games
  • My Story
  • Chat
  • Contact Us
home shop notifications more
Signin
  •  Profile
  •  Sign Out
Skip to content

Billionaire Club Co LLC

Believe It and You Will Achieve It

Primary Menu
  • Home
  • Politics
  • TSR
  • Anime
  • Michael Jordan vs.Lebron James
  • Crypto
  • Soccer
  • Dating
  • Airplanes
  • Forex
  • Tax
  • New Movies Coming Soon
  • Games
  • CRYPTO INSURANCE
  • Sport
  • MEMES
  • K-POP
  • AI
  • The Bahamas
  • Digital NoMad
  • Joke of the Day
  • RapVerse
  • Stocks
  • SPORTS BETTING
  • Glamour
  • Beauty
  • Travel
  • Celebrity Net Worth
  • TMZ
  • Lotto
  • COVD-19
  • Fitness
  • The Bible is REAL
  • OutDoor Activity
  • Lifestyle
  • Culture
  • Boxing
  • Food
  • LGBTQ
  • Poetry
  • Music
  • Misc
  • Open Source
  • NASA
  • Science
  • Natural & Holstict Med
  • Gardening
  • DYI
  • History
  • Art
  • Education
  • Pets
  • Aliens
  • Astrology
  • Farming and LiveStock
  • LAW
  • Fast & Furious
  • Fishing & Hunting
  • Health
  • Credit Repair
  • Grants
  • All things legal
  • Reality TV
  • Africa Today
  • China Today
  • "DUMB SHIT.."
  • Stocks

Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers

Getty Images

Key TakeawaysThe Food and Drug Administration approved Geron's drug Rytelo for those with rare blood cancers who are suffering from anemia.Geron said Rytelo could triple the time before affected patients need to get their next red blood cell transfusion.The news sent shares of Geron soaring over 19% in intraday trading Friday.
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company’s drug Rytelo for those with rare blood cancers.Geron’s Rytelo is for adults who suffer from low- to intermediate-1 risk myelodysplastic syndromes (MDS) and need to receive transfusions of four or more red blood cell units over eight weeks.Geron Says Rytelo Could Help Extend Time Between TransfusionsGeron CEO John Scarlett said that those taking Rytelo potentially could go for more than 24 weeks without transfusions and symptomatic anemia. Rami Komrokji, who was an investigator in the injectable drug’s Phase 3 trial, said that for patients with lower-risk MDS and anemia who need blood transfusions, there are few options available. He noted that the addition of Rytelo could be “potentially practice-changing for us.”Geron's Rytelo Could Compete With Bristol Myers Squibb's ReblozyRytelo is expected to compete with Bristol Myers Squibb’s (BMY) Reblozyl, which the FDA approved last summer.Geron said it plans “to ensure broad access” to Rytelo for those eligible to take it. The wholesale cost will be $9,884 for the 188-milligram (mg) vial, and $2,471 for the 47-mg size, Reuters reported. A common dose of Rytelo is 7.1 mg of the drug per kilogram of patient weight.Geron shares soared over 19% to $4.67 as of 3:15 p.m. ET Friday following the news. They've more than doubled in value so far this year.

TradingView

Read the original article on Investopedia.

Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!

Source link

Share
What's your thought on the article, write a comment
0 Comments
×

Sign In to perform this Activity

Sign in
×

Account Frozen

Your account is frozen. You can still view content but cannot interact with it.

Please go to your settings to update your account status.

Open Profile Settings

Ads

  • Premium Billionaire128 Unisex Long Sleeve Tee

    $ 25.00
  • Billionaire128 Liquid Gold Flip-Flops

    $ 18.00
  • Original Billionaire128 Fanny Pack

    $ 35.00
  • News Social

    • Facebook
    • Twitter
    • Facebook
    • Twitter
    Copyright © 2024 Billionaire Club Co LLC. All rights reserved